Gland Pharma reports 41 percent jump in Q1 revenue

Gland Pharma, majority owned by China's Shanghai Fosun Pharmaceutical Group Co, however, reported a 15.3% fall in profit to 1.94 billion rupees for the quarter ended June 30 amid price erosions and increased competition.

Published On 2023-08-08 09:00 GMT   |   Update On 2023-08-08 09:00 GMT
Advertisement

Hyderabad: Indian generic injectables maker Gland Pharma Ltd reported a 41% jump in first-quarter revenue on Monday, aided by its acquisition of French pharmaceutical group Cenexi.

The Hyderabad-based company, which draws the bulk of its revenue from the United States, Europe, Canada, Australia and New Zealand, said revenue jumped to 12.09 billion Indian rupees ($146.13 million) from 8.57 billion rupees.

Advertisement

The company said 37% of the total revenue came from its acquisition of Cenexi in January. Revenue from Europe jumped more than five-fold to 2.22 billion rupees.

Excluding the Cenexi acquisition, Gland Pharma's revenue rose 3.5% on the back of improvement in its base business and stability in the United States.

"The efforts made for business recovery, after a challenging previous year, are yielding fruitful results," Gland Pharma Chief Executive Officer Srinivas Sadu said in a statement.

Gland Pharma, majority owned by China's Shanghai Fosun Pharmaceutical Group Co, however, reported a 15.3% fall in profit to 1.94 billion rupees for the quarter ended June 30 amid price erosions and increased competition.

Gland Pharma, founded in 1978, primarily operates on a business-to-business model and focuses on sterile and complex injectables. The company also has contract manufacturing, along with direct consumer sales.

Sales in the Indian market, which accounts for 5% of its total revenue, rose 29% to 647 million rupees.

Gland Pharma also said it launched cardioprotective agent Dexrazoxane in China during the quarter, the company's first product in the country.

Read also: Gland Pharma reports 56 percent decline in Q4 profit on soft demand

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News